Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rainer Abel

Showing results (61-70 of 63) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 63 results.
Nature Communications|May 12, 2026
Anti-Nogo-A NG101 treatment induces changes in spinal cord micro- and macrostructure following spinal cord injuryLynn Farner, Paulina S Scheuren, Kiomars Sharifi, et al.
Journal of Neurotrauma|July 9, 2026
The Integrated Neurological Change Score Is a Sensitive Neurological Composite Measure to Evaluate Cervical Spinal Cord Injury TrialsAngel Arevalo-Martin, Catherine Jutzeler, Daniel Garcia-Ovejero, et al.
The Lancet. Neurology|December 20, 2024
Safety and efficacy of intrathecal antibodies to Nogo-A in patients with acute cervical spinal cord injury: a randomised, double-blind, multicentre, placebo-controlled, phase 2b trialNorbert Weidner, Rainer Abel, Doris Maier, et al.
Pageof 7

Showing results (61-70 of 63) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 63 results.
Nature Communications|May 12, 2026
Anti-Nogo-A NG101 treatment induces changes in spinal cord micro- and macrostructure following spinal cord injuryLynn Farner, Paulina S Scheuren, Kiomars Sharifi, et al.
Journal of Neurotrauma|July 9, 2026
The Integrated Neurological Change Score Is a Sensitive Neurological Composite Measure to Evaluate Cervical Spinal Cord Injury TrialsAngel Arevalo-Martin, Catherine Jutzeler, Daniel Garcia-Ovejero, et al.
The Lancet. Neurology|December 20, 2024
Safety and efficacy of intrathecal antibodies to Nogo-A in patients with acute cervical spinal cord injury: a randomised, double-blind, multicentre, placebo-controlled, phase 2b trialNorbert Weidner, Rainer Abel, Doris Maier, et al.
Pageof 7